Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study
Brain Sciences · 12.01.2023 · 13 (1) · 133
DOI: 10.3390/brainsci13010133 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Brain Sciences, online erschienen am 12.01.2023. Verfasst von Boney Joseph und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, The J. Willard and Alice S. Marriott Foundation, Mayo Clinic Center for Individualized Medicine.
Abstract (Originalsprache)
Lithium has been a cornerstone treatment for bipolar disorder (BD). Despite descriptions in the literature regarding associations between long-term lithium therapy (LTLT) and development of a thyroid disorder (overt/subclinical hypo/hyperthyroidism, thyroid nodule, and goiter) in BD, factors such as time to onset of thyroid abnormalities and impact on clinical outcomes in the course of illness have not been fully characterized. In this study we aimed to compare clinical characteristics of adult BD patients with and without thyroid disorders who were on LTLT. We aimed to identify the incidence of thyroid disorders in patients with BD on LTLT and response to lithium between patients with and without thyroid disorders in BD. The Cox proportional model was used to find the median time to the development of a thyroid disorder. Our results showed that up to 32% of patients with BD on LTLT developed a thyroid disorder, of which 79% developed hypothyroidism, which was corrected with thyroid hormone replacement. We did not find significant differences in lithium response between patients with or without thyroid disorders in BD. Findings from this study suggest that patients with BD and comorbid thyroid disorders when adequately treated have a response to lithium similar to patients with BD and no thyroid disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
- Lindner Center of HOPE, Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati, Cincinnati, OH 45040, USA.
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Boney Joseph, Rakesh Kumar, Mete Ercis, Marius N Stan, Balwinder Singh
Förderung
- NIGMS NIH HHS
- The J. Willard and Alice S. Marriott Foundation
- Mayo Clinic Center for Individualized Medicine
Zitieren
APA
Joseph, B., Nunez, N. A., Pazdernik, V., Kumar, R., Pahwa, M., Ercis, M., Ozerdem, A., Cuellar-Barboza, A. B., Romo-Nava, F., McElroy, S. L., Coombes, B. J., Biernacka, J. M., Stan, M. N., Frye, M. A., & Singh, B. (2023). Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study. Brain Sciences, 13(1), 133. https://doi.org/10.3390/brainsci13010133
Vancouver
Joseph B, Nunez NA, Pazdernik V, Kumar R, Pahwa M, Ercis M, et al. Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study. Brain Sciences. 2023;13(1):133. doi:10.3390/brainsci13010133
BibTeX
@article{Joseph2023,
author = {Joseph, Boney and Nunez, Nicolas A and Pazdernik, Vanessa and Kumar, Rakesh and Pahwa, Mehak and Ercis, Mete and Ozerdem, Aysegul and Cuellar-Barboza, Alfredo B and Romo-Nava, Francisco and McElroy, Susan L and Coombes, Brandon J and Biernacka, Joanna M and Stan, Marius N and Frye, Mark A and Singh, Balwinder},
title = {Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study},
journal = {Brain Sciences},
year = {2023},
volume = {13},
number = {1},
pages = {133},
doi = {10.3390/brainsci13010133}
}
EUVIMED